{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Aurinia Pharmaceuticals Inc"},"Symbol":{"label":"Symbol","value":"AUPH"},"Address":{"label":"Address","value":"4464 MARKHAM STREET,SUITE 1203, VICTORIA, British Columbia, V8Z 7X8, Canada"},"Phone":{"label":"Phone","value":"+1 250 708-4272"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing voclosporin, an investigational drug, for the treatment of lupus nephritis (LN), focal segmental glomerulosclerosis (FSGS), and Dry Eye Syndrome (DES). Geographically, it derives maximum revenue from the United States."},"CompanyUrl":{"label":"Company Url","value":"https://www.auriniapharma.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Matthew Maxwell Donley","title":"Executive Vice President-Operations & Strategy"},{"name":"Peter S. Greenleaf","title":"President, Chief Executive Officer & Director"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}